Providing Answers, Support and Hope in Ohio
The advancement of medicine depends upon millions of people who volunteer to participate in clinical studies or trials every year. Participating in research is essential for furthering the understanding of lupus and other diseases and, ultimately, leads to more effective treatments.
If you're wondering how clinical trials work, take a look at our frequently asked questions about participating in clinical trials. This includes the basics of clinical trials, how to get started, what is involved in being a part of a clinical trial and more.
Featured clinical trials
In collaboration with research partners, the Lupus Foundation of America goes to great lengths to educate and raise awareness about the rights of clinical trial volunteers, opportunities to engage in research, and the importance of clinical trial participation. Learn more about some of the lupus trials currently enrolling.
The purpose of these two identical studies is to assess the efficacy, safety, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active moderate to severe systemic lupus erythematosus (SLE).
The TOPAZ studies are evaluating an investigational medication in SLE patients who are taking SLE non-biologic therapy.
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory systemic lupus erythematosus (srSLE). Patients with srSLE have a type of lupus that does not go into remission despite receiving appropriate therapies.
The SELECT-SLE Research Study is a clinical research study designed to evaluate the safety and efficacy of the investigational drug compared to placebo in reducing disease activity/flares and improving the quality of life for participants living with lupus (SLE, Systemic Lupus Erythematosus). Participants receive either the investigational drug or a placebo (something that looks like the investigational drug, but has no effect on the body). Both the investigational drug and placebo will be administered as oral treatments on top of other lupus treatments participants are already receiving.
A phase II-controlled trial of human allogeneic umbilical cord-derived mesenchymal stromal cells (MSCs) for the Treatment of Refractory Lupus.
The purpose of the RestoreD Study is to evaluate the safety and effectiveness of an oral investigational medication, called ALXN 2050, given in addition to standard of care and compared with placebo in reducing symptoms in adults with LN and IgAN.
The purpose of this clinical trial is to determine whether the investigational drug, afimetoran, is safe and effective in treating patients with active systemic lupus erythematosus with symptoms compared with placebo. A placebo is a substance that looks like the study medication but contains no active ingredients. The study also hopes to determine if there is one dose that works better than another.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
Search for clinical trials
Antidote provides a services that allows you to search for clinical trials based on both your location and your specific condition.
Know your options | Access the latest treatments | Receive world-class care
About Antidote: Antidote delivers clear, unbiased information about clinical trial options. We aim to match you to the best trial, regardless of sponsor. Find Antidote's privacy policy here.
Other ways to find clinical trials
Search these sites to find information about clinical trials near you.
- ClinicalTrials.gov - a registry of both publicly and privately supported clinical studies maintained by the US National Institutes of Health.
- CenterWatch.com - the largest online listing of industry-sponsored global clinical trials.
RAY: Research Accelerated by You is a lupus data platform where people with lupus and caregiversprovide information about their lupus experience. Help brighten the future of lupus research.